BACKGROUND: Although prothrombin complex concentrate (PCC) is often used to counteract vitamin K antagonist (VKA) therapy, evidence regarding the optimal dose for this indication is lacking. In Dutch hospitals, either a variable dose, based on body weight, target INR (international normalised ratio) and initial INR, or a fixed dose is used. AIM/ OBJECTIVES: In this observational, pilot study, the efficacy and feasibility of the fixed dose strategy compared to the variable dosing regimen, is investigated. MATERIALS AND METHODS: Consecutive patients receiving PCC (Cofact®, Sanquin, Amsterdam) for VKA reversal because of a major non-cranial bleed or an invasive procedure were enrolled in two cohorts. Data were collected prospectively in the fixed dose group, cohort 1, and retrospectively in the variable dose regimen, cohort 2. Study endpoints were proportion of patients reaching target INR and successful clinical outcome. RESULTS: Cohort 1 consisted of 35 and cohort 2 of 32 patients. Target INR was reached in 70% of patients in cohort 1 versus 81% in cohort 2 (P = 0·37). Successful clinical outcome was seen in 91% of patients in cohort 1 versus 94% in cohort 2 (P = 1·00). Median INR decreased from 4·7 to 1·8 with a median dosage of 1040 IU factor IX (F IX) in cohort 1 and from 4·7 to 1·6 with a median dosage of 1580 IU F IX in cohort 2. CONCLUSION: This study suggests that a fixed dose of 1040 IU of F IX may be an effective way to rapidly counteract VKA therapy in our patient population and provides a basis for future research.
BACKGROUND: Although prothrombin complex concentrate (PCC) is often used to counteract vitamin K antagonist (VKA) therapy, evidence regarding the optimal dose for this indication is lacking. In Dutch hospitals, either a variable dose, based on body weight, target INR (international normalised ratio) and initial INR, or a fixed dose is used. AIM/ OBJECTIVES: In this observational, pilot study, the efficacy and feasibility of the fixed dose strategy compared to the variable dosing regimen, is investigated. MATERIALS AND METHODS: Consecutive patients receiving PCC (Cofact®, Sanquin, Amsterdam) for VKA reversal because of a major non-cranial bleed or an invasive procedure were enrolled in two cohorts. Data were collected prospectively in the fixed dose group, cohort 1, and retrospectively in the variable dose regimen, cohort 2. Study endpoints were proportion of patients reaching target INR and successful clinical outcome. RESULTS: Cohort 1 consisted of 35 and cohort 2 of 32 patients. Target INR was reached in 70% of patients in cohort 1 versus 81% in cohort 2 (P = 0·37). Successful clinical outcome was seen in 91% of patients in cohort 1 versus 94% in cohort 2 (P = 1·00). Median INR decreased from 4·7 to 1·8 with a median dosage of 1040 IU factor IX (F IX) in cohort 1 and from 4·7 to 1·6 with a median dosage of 1580 IU F IX in cohort 2. CONCLUSION: This study suggests that a fixed dose of 1040 IU of F IX may be an effective way to rapidly counteract VKA therapy in our patient population and provides a basis for future research.
Authors: Santiago R Leal-Noval; Manuel Muñoz; Marisol Asuero; Enric Contreras; José A García-Erce; Juan V Llau; Victoria Moral; José A Páramo; Manuel Quintana Journal: Blood Transfus Date: 2013-06-17 Impact factor: 3.443
Authors: Nakisa Khorsand; Lisette Giepmans; Karina Meijer; Reinier M van Hest; Nic J G M Veeger Journal: Haematologica Date: 2013-05-03 Impact factor: 9.941
Authors: Wesley R Zemrak; Kathryn E Smith; Stephen S Rolfe; Teresa May; Robert L Trowbridge; Timothy L Hayes; Gene A Grindlinger; David B Seder Journal: Neurocrit Care Date: 2017-12 Impact factor: 3.210
Authors: Wesley Zemrak; Francis Manuel; Kathryn E Smith; Stephen Rolfe; Timothy Hayes; Robert L Trowbridge; Brian Carlone; David Seder Journal: J Thromb Thrombolysis Date: 2019-02 Impact factor: 2.300
Authors: G Morgan Jones; Michael J Erdman; Keaton S Smetana; Kerry M Mohrien; Joseph E Vandigo; Lucas Elijovich Journal: J Thromb Thrombolysis Date: 2016-07 Impact factor: 2.300
Authors: Nakisa Khorsand; Nic J G M Veeger; Reinier M van Hest; Paula F Ypma; Jeroen Heidt; Karina Meijer Journal: Haematologica Date: 2012-04-04 Impact factor: 9.941
Authors: Carmen Sobrino Jiménez; José Antonio Romero-Garrido; Ángeles García-Martín; Manuel Quintana-Díaz; Carlos Jiménez-Vicente; Luis González-Del Valle; Alicia Herrero Ambrosio; Juana Benedí-González Journal: Eur J Hosp Pharm Date: 2020-06-26